Premium
Safety and efficacy of aprepitant for chemotherapy‐induced nausea and vomiting in pediatric patients: A prospective, observational study
Author(s) -
Bodge Megan,
Shillingburg Alexandra,
Paul Stephan,
Biondo Lisa
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24901
Subject(s) - aprepitant , medicine , nausea , antiemetic , vomiting , blood cancer , chemotherapy , observational study , incidence (geometry) , anesthesia , cancer , physics , optics
Pediatric patients between the ages of 12 months and 17 years with a confirmed malignancy who were scheduled to receive aprepitant as part of triple therapy antiemetic prophylaxis for a cycle of moderately‐ or highly emetogenic chemotherapy were eligible for enrollment. Patients were evaluated for the incidence of nausea, episodes of emesis, interference with activities of daily living (ADLs), and appetite through utilization of a patient survey. Eleven patients were enrolled for a total of 20 patient encounters, mean age 9.55 ± 4.85 (range, 12 months–17 years). Aprepitant was well‐tolerated and complete response (CR) rate was 38.9%. Pediatr Blood Cancer 2014;61:1111–1113. © 2013 Wiley Periodicals, Inc.